31 results
8-K
GLTO
Galecto Inc
21 Dec 23
Other Events
4:30pm
endpoint of the MYLOX-1 trial was to assess the safety and tolerability of GB2064.
Apart from evaluating the safety and tolerability of GB2064, key
8-K
EX-99.1
GLTO
Galecto Inc
23 Oct 23
Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial
9:00am
the safety and efficacy of GB1211 in combination with pembrolizumab (Keytruda®). Galecto plans to explore external options for partnering and/or funding … oncology trials. Part B of the GALLANT-1 trial had been designed to evaluate safety and tumor shrinkage in NSCLC patients and explore tumor response rate
8-K
EX-99.1
b5izpd3ztj
15 Aug 23
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
8:00am
8-K
m0uf0gl
15 Aug 23
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
8:00am
8-K
EX-99.1
kc9qon184d qq0fv
31 Oct 22
Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD’s The Liver Meeting® 2022
9:00am
8-K
vxernfp8kionrsn0x8
29 Sep 22
GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target
7:00am
8-K
EX-99.1
fo3v un3p
29 Sep 22
GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target
7:00am
8-K
EX-99.1
i8b5 ydxf
27 Jan 22
Results Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lung Disease
8:31am
8-K
EX-99.1
oar5x 5j4wk9ett
5 Jan 22
Regulation FD Disclosure
4:02pm
S-3
yws8iri
4 Nov 21
Shelf registration
4:59pm